← All drugs
Drug · FAERS side-effect profile with label screen

Metoclopramide side effects: what 54,571 FDA adverse event reports show

Metoclopramide · 1,230 reaction terms · 258,823 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

54,571 reports · 94% serious · 7,242 with death outcome · 62% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. Relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

FDA label, Indications and Usage

What it is

Metoclopramide hydrochloride, USP, the active ingredient of metoclopramide tablets, USP is a dopamine-2 receptor antagonist. Metoclopramide hydrochloride (metoclopramide monohydrochloride monohydrate) is a white or practically white, crystalline, odorless or practically odorless powder.

FDA label, Description section

Boxed warning

TARDIVE DYSKINESIA Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. There is no known treatment for TD. The risk of developing TD increases with duration of treatment and total cumulative dosage [ see Warnings and Precautions ( 5.1 ) ].

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 3Labeled adverse reaction 5Labeled (related wording) 3Likely indication confounding 1Reporting / coding artifact 4Not in label — unassessed 24
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,190 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Computerised tomogram thorax39702.3
413.2–1,193.7ROR 702.8 · calibrated p 7e-14 ✓
220.0 EB05 167.9 · IC025 +5.4
3/3 methods agree
Not in label — unassessedserious n=39 · ♀ 100% (drug 62%) · 100% clinicianno trial arm names this drug
Family stress1,920615.8
573.0–661.8ROR 638.2 · calibrated p 4e-15 ✓
234.4 EB05 225.7 · IC025 +7.7
3/3 methods agree
Not in label — unassessedserious n=1,920no trial arm names this drug
Extrapyramidal disorder11,637335.5
327.7–343.4ROR 426.1 · calibrated p 3e-13 ✓
178.2 EB05 175.5 · IC025 +7.4
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 8.4 · serious PRR 118.3 · 73% consumerno trial arm names this drug
Tardive dyskinesia (persistent involuntary movements)13,206335.0
327.7–342.4ROR 441.6 · calibrated p 2e-13 ✓
178.0 EB05 175.5 · IC025 +7.4
3/3 methods agree
Labeled — boxed warning
exact term
serious PRR 127.8 · 78% consumerno trial arm names this drug
Dystonia6,682201.7
196.0–207.5ROR 229.7 · calibrated p 1e-10 ✓
131.8 EB05 129.2 · IC025 +7.0
3/3 methods agree
Not in label — unassessedserious PRR 88.1no trial arm names this drug
Multiple injuries2,127193.1
183.4–203.3ROR 200.9 · calibrated p 4e-10 ✓
128.0 EB05 123.5 · IC025 +6.9
3/3 methods agree
Not in label — unassessedserious n=2,126 · 100% consumerno trial arm names this drug
Grimacing222153.8
131.6–179.7ROR 154.4 · calibrated p 4e-9 ✓
108.6 EB05 97.1 · IC025 +6.2
3/3 methods agree
Labeled adverse reaction
exact term
serious n=220no trial arm names this drug
Deformity2,327127.1
121.4–133.1ROR 132.7 · calibrated p 1e-8 ✓
95.3 EB05 92.1 · IC025 +6.5
3/3 methods agree
Not in label — unassessedserious PRR 66.5 · 100% consumerno trial arm names this drug
Economic problem3,755124.0
119.6–128.5ROR 133.0 · calibrated p 1e-8 ✓
93.6 EB05 91.1 · IC025 +6.5
3/3 methods agree
Reporting / coding artifactserious PRR 61.7 · 100% consumerno trial arm names this drug
Nervous system disorder7,176114.4
111.5–117.3ROR 131.5 · calibrated p 1e-8 ✓
88.0 EB05 86.3 · IC025 +6.4
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.4 · serious PRR 60.0no trial arm names this drug
Excessive eye blinking28491.4
80.3–104.0ROR 91.9 · calibrated p 2e-7 ✓
73.5 EB05 66.6 · IC025 +5.8
3/3 methods agree
Not in label — unassessedserious n=283no trial arm names this drug
Vaginal flatulence5278.7
58.4–106.0ROR 78.7 · calibrated p 1e-6 ✓
63.8 EB05 50.5 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=52 · ♀ 100% (drug 62%)no trial arm names this drug
Quality of life decreased2,03868.7
65.6–71.9ROR 71.3 · calibrated p 1e-6 ✓
58.2 EB05 56.2 · IC025 +5.8
3/3 methods agree
Not in label — unassessedserious PRR 43.7no trial arm names this drug
Activities of daily living impaired2,75961.1
58.8–63.6ROR 64.3 · calibrated p 3e-6 ✓
52.8 EB05 51.1 · IC025 +5.6
3/3 methods agree
Not in label — unassessedserious PRR 43.2 · 71% consumerno trial arm names this drug
Parkinson's disease33256.7
50.6–63.6ROR 57.1 · calibrated p 6e-6 ✓
49.3 EB05 45.0 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=311no trial arm names this drug
Akathisia (inner restlessness)1,61451.5
48.9–54.2ROR 53.0 · calibrated p 9e-6 ✓
45.4 EB05 43.6 · IC025 +5.4
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 38.8no trial arm names this drug
Chorea18445.7
39.2–53.2ROR 45.8 · calibrated p 3e-5 ✓
40.7 EB05 36.0 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious n=174no trial arm names this drug
Peripheral circulatory failure4345.0
32.8–61.8ROR 45.1 · calibrated p 4e-5 ✓
39.7 EB05 30.7 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=43 · ♀ 100% (drug 62%) · 100% clinicianno trial arm names this drug
Computerised tomogram thorax abnormal7143.5
34.0–55.6ROR 43.6 · calibrated p 4e-5 ✓
38.8 EB05 31.8 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=71 · ♀ 100% (drug 62%) · 100% clinicianno trial arm names this drug
Movement disorder2,87037.5
36.1–38.9ROR 39.5 · calibrated p 6e-5 ✓
34.2 EB05 33.1 · IC025 +5.0
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 1.2 · serious PRR 26.6 · 73% consumerno trial arm names this drug
Incorrect drug administration duration2,48836.7
35.2–38.2ROR 38.4 · calibrated p 7e-5 ✓
33.5 EB05 32.4 · IC025 +5.0
3/3 methods agree
Reporting / coding artifactage-adj. PRR 0.2 · serious PRR 56.0 · 100% consumerno trial arm names this drug
Multiple drug therapy5734.1
26.0–44.7ROR 34.1 · calibrated p 2e-4 ✓
31.1 EB05 24.9 · IC025 +4.2
3/3 methods agree
Reporting / coding artifactserious n=57 · ♀ 100% (drug 62%) · 100% clinicianno trial arm names this drug
Stereotypy7633.9
26.8–42.8ROR 33.9 · calibrated p 2e-4 ✓
30.9 EB05 25.5 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=75no trial arm names this drug
Pre-existing disease3832.0
23.0–44.6ROR 32.0 · calibrated p 3e-4 ✓
29.2 EB05 22.2 · IC025 +3.9
3/3 methods agree
Reporting / coding artifactserious n=38 · ♀ 100% (drug 62%)no trial arm names this drug
Partner stress7230.9
24.3–39.2ROR 30.9 · calibrated p 3e-4 ✓
28.4 EB05 23.3 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=71no trial arm names this drug
Dyskinesia (involuntary movements)2,56125.8
24.9–26.9ROR 27.1 · calibrated p 4e-4 ✓
24.3 EB05 23.5 · IC025 +4.5
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 3.2 · serious PRR 19.4no trial arm names this drug
Fear1,69125.5
24.3–26.8ROR 26.3 · calibrated p 5e-4 ✓
24.0 EB05 23.0 · IC025 +4.5
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.2 · serious PRR 19.8no trial arm names this drug
Anhedonia1,63725.3
24.0–26.5ROR 26.0 · calibrated p 6e-4 ✓
23.7 EB05 22.8 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious PRR 16.0 · 100% consumerno trial arm names this drug
Metabolic disorder32923.0
20.6–25.7ROR 23.2 · calibrated p 0.001 ✓
21.8 EB05 19.8 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=328no trial arm names this drug
Phaeochromocytoma3521.3
15.1–29.9ROR 21.3 · calibrated p 0.002 ✓
20.0 EB05 15.0 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=35 · ♀ 100% (drug 62%) · 100% clinicianno trial arm names this drug
Aplastic anaemia26520.4
18.0–23.1ROR 20.5 · calibrated p 0.002 ✓
19.4 EB05 17.5 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=265 · 95% clinicianno trial arm names this drug
Neutropenic sepsis36020.3
18.3–22.6ROR 20.4 · calibrated p 0.002 ✓
19.3 EB05 17.7 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious PRR 11.7 · 94% clinicianno trial arm names this drug
Parkinsonism44518.3
16.7–20.2ROR 18.5 · calibrated p 0.003 ✓
17.5 EB05 16.2 · IC025 +3.9
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 12.1no trial arm names this drug
Systemic infection7518.1
14.4–22.8ROR 18.1 · calibrated p 0.003 ✓
17.2 EB05 14.2 · IC025 +3.6
3/3 methods agree
Labeled adverse reaction
exact term
serious n=75 · ♀ 29% (drug 62%) · 100% clinicianno trial arm names this drug
Nephrogenic anaemia20017.1
14.9–19.7ROR 17.2 · calibrated p 0.004 ✓
16.4 EB05 14.6 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=200no trial arm names this drug
Hyperparathyroidism secondary10516.6
13.6–20.2ROR 16.6 · calibrated p 0.005 ✓
15.9 EB05 13.5 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=105no trial arm names this drug
Chronic kidney disease-mineral and bone disorder4014.8
10.8–20.3ROR 14.8 · calibrated p 0.009 ✓
14.0 EB05 10.6 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=40no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Extrapyramidal15,20164.863.8–65.7signal
Neutropenia / agranulocytosis3,2845.25.0–5.3signal
Hyponatraemia7983.83.6–4.1signal
Severe cutaneous reaction5272.72.5–3.0signal
Kidney injury3,2042.72.6–2.8signal
Anaemia2,0982.72.6–2.8signal
Arrhythmia / qt1,2312.52.3–2.6signal
Thrombocytopenia1,3162.32.2–2.4signal
Anaphylaxis / angioedema6682.11.9–2.2raised
Interstitial lung disease5002.01.8–2.2raised
Gi bleeding9251.91.8–2.1raised
Pancreatitis3901.91.7–2.1raised
Serious infection3,6791.81.8–1.9raised
Depression1,2911.81.7–1.9raised
Liver injury1,3791.81.7–1.9raised
Venous thromboembolism9741.71.6–1.8raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Metoclopramide only as a background or rescue medication (NCT02625181, NCT01636947); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Tardive dyskinesia (persistent involuntary movements)13,206335.0
327.7–342.4ROR 441.6 · calibrated p 2e-13 ✓
178.0 EB05 175.5 · IC025 +7.4
3/3 methods agree
Labeled — boxed warning
exact term
serious PRR 127.8 · 78% consumerno trial arm names this drug
Extrapyramidal disorder11,637335.5
327.7–343.4ROR 426.1 · calibrated p 3e-13 ✓
178.2 EB05 175.5 · IC025 +7.4
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 8.4 · serious PRR 118.3 · 73% consumerno trial arm names this drug
Nervous system disorder7,176114.4
111.5–117.3ROR 131.5 · calibrated p 1e-8 ✓
88.0 EB05 86.3 · IC025 +6.4
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.4 · serious PRR 60.0no trial arm names this drug
Dystonia6,682201.7
196.0–207.5ROR 229.7 · calibrated p 1e-10 ✓
131.8 EB05 129.2 · IC025 +7.0
3/3 methods agree
Not in label — unassessedserious PRR 88.1no trial arm names this drug
Pain4,7233.0
2.9–3.0ROR 3.2 · calibrated p 0.579
2.9 EB05 2.9 · IC025 +1.5
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.2 · serious PRR 2.8no trial arm names this drug
Nausea4,0842.0
1.9–2.1ROR 2.1 · calibrated p 0.984
2.0 EB05 1.9 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 2.4 · serious PRR 2.2no trial arm names this drug
Economic problem3,755124.0
119.6–128.5ROR 133.0 · calibrated p 1e-8 ✓
93.6 EB05 91.1 · IC025 +6.5
3/3 methods agree
Reporting / coding artifactserious PRR 61.7 · 100% consumerno trial arm names this drug
Vomiting3,2622.7
2.6–2.8ROR 2.8 · calibrated p 0.698
2.7 EB05 2.6 · IC025 +1.4
3/3 methods agree
Not in label — unassessedage-adj. PRR 3.1 · serious PRR 2.3no trial arm names this drug
Anxiety3,2144.4
4.2–4.5ROR 4.6 · calibrated p 0.286
4.3 EB05 4.2 · IC025 +2.1
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 3.8no trial arm names this drug
Movement disorder2,87037.5
36.1–38.9ROR 39.5 · calibrated p 6e-5 ✓
34.2 EB05 33.1 · IC025 +5.0
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 1.2 · serious PRR 26.6 · 73% consumerno trial arm names this drug
Diarrhoea (diarrhea)2,7721.7
1.6–1.7ROR 1.7 · calibrated p 0.765
1.7 EB05 1.6 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 2.0 · serious PRR 1.7no trial arm names this drug
Activities of daily living impaired2,75961.1
58.8–63.6ROR 64.3 · calibrated p 3e-6 ✓
52.8 EB05 51.1 · IC025 +5.6
3/3 methods agree
Not in label — unassessedserious PRR 43.2 · 71% consumerno trial arm names this drug
Dyskinesia (involuntary movements)2,56125.8
24.9–26.9ROR 27.1 · calibrated p 4e-4 ✓
24.3 EB05 23.5 · IC025 +4.5
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 3.2 · serious PRR 19.4no trial arm names this drug
Incorrect drug administration duration2,48836.7
35.2–38.2ROR 38.4 · calibrated p 7e-5 ✓
33.5 EB05 32.4 · IC025 +5.0
3/3 methods agree
Reporting / coding artifactage-adj. PRR 0.2 · serious PRR 56.0 · 100% consumerno trial arm names this drug
Deformity2,327127.1
121.4–133.1ROR 132.7 · calibrated p 1e-8 ✓
95.3 EB05 92.1 · IC025 +6.5
3/3 methods agree
Not in label — unassessedserious PRR 66.5 · 100% consumerno trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Metoclopramide ↔ Tardive dyskinesia.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Metoclopramide?

In FDA FAERS, the most frequently co-reported reaction terms for Metoclopramide are tardive dyskinesia, extrapyramidal disorder, nervous system disorder, dystonia, pain, nausea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Metoclopramide have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: TARDIVE DYSKINESIA Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. There is no known treatment for TD. The risk of developing TD increases with duration of treatment and total cumulative dosage [ see Warnings and Precautions ( 5.1 ) ].

Do FAERS signals prove that Metoclopramide causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.